Scarica l'app Stockscreener
556.55
1.94%
10.61
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$545.94
Aprire:
$547.94
Volume 24 ore:
762.59K
Relative Volume:
0.63
Capitalizzazione di mercato:
$57.98B
Reddito:
$14.21B
Utile/perdita netta:
$4.46B
Rapporto P/E:
14.03
EPS:
39.68
Flusso di cassa netto:
$3.56B
1 W Prestazione:
-2.34%
1M Prestazione:
-1.97%
6M Prestazione:
-16.16%
1 anno Prestazione:
-50.36%
Intervallo 1D:
$547.09
$562.74
Intervallo di 1 settimana:
$544.16
$573.47
Portata 52W:
$476.49
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Confronta REGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Deutsche Bank AG Has $344.45 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Forsta AP Fonden Sells 1,300 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Maryland State Retirement & Pension System Cuts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Swiss National Bank - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Mitsubishi UFJ Asset Management Co. Ltd. - MarketBeat
Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know - FinancialContent
Charles Schwab Investment Management Inc. Raises Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Truist Financial Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $812.00 - MarketBeat
Sanofi halts China sales of cholesterol drug Praluent (SNY) - Seeking Alpha
Guggenheim Lifts PT on Regeneron Pharmaceuticals (REGN) to $815 From $810 - Insider Monkey
Knott David M Jr Takes $1.27 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Invesco Ltd. Has $539.57 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by AIA Group Ltd - MarketBeat
Sanofi stops supply of high cholesterol drug to China due to limited availability - The Mighty 790 KFGO
Regeneron Reveals The Regeneron Prize For Creative Innovation 2025 Winners - MSN
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stake Reduced by National Bank of Canada FI - MarketBeat
Nuveen LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Cary Street Partners Financial LLC Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
ASR Vermogensbeheer N.V. Buys Shares of 9,485 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Headlands Technologies LLC Decreases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Regeneron: EYLEA's Decline Is Masking A Deep Value Opportunity (NASDAQ:REGN) - Seeking Alpha
This Stock Has Tumbled 50% In One Year, Gets A Price Target Cut Today – But Retail Believes $400-450 Is A Good Entry Point - Stocktwits
Truist Securities lowers Regeneron Pharma stock price target on Eylea concerns - Investing.com
A Look Into Regeneron Pharmaceuticals Inc's Price Over Earnings - Benzinga
Follicular Lymphoma Market Trends Point to Steady Growth Ahead - openPR.com
Follicular Lymphoma Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals | Roche, MEI Pharma, Novartis, Innovent Biologics, Regeneron, Genentech, Xynomic Pharma, Eli Lilly - Barchart.com
Truist Securities Adjusts Regeneron Pharmaceuticals Price Target to $812 From $940, Maintains Buy Rating - MarketScreener
Zymeworks Strengthens Board with Healthcare Veterans as Key Trial Results Near - Stock Titan
Mizuho Securities USA LLC Has $5.34 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Townsquare Capital LLC Grows Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Entropy Technologies LP - MarketBeat
What Regeneron Pharmaceuticals (REGN)'s Strong Q2 Results and Dupixent FDA Approval Mean For Shareholders - simplywall.st
Cornerstone Advisors LLC Has $3.87 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Citizens Financial Group Inc. RI Sells 465 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
BMO Capital Lifts PT on Regeneron Pharmaceuticals (REGN) Stock, Keeps Outperform - MSN
New Age Alpha Advisors LLC Trims Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
11 Best GLP-1 and Weight Loss Stocks to Invest in - Insider Monkey
Goldman Sachs Group Inc. Raises Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Asthma Treatment - The Globe and Mail
Regeneron Pharmaceuticals, Inc. Plans Quarterly Dividend of $0.88 (NASDAQ:REGN) - MarketBeat
Empire Life Investments Inc. Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by ING Groep NV - MarketBeat
3,000 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by American Assets Investment Management LLC - MarketBeat
PNC Financial Services Group Inc. Sells 755 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
iA Global Asset Management Inc. Buys 7,586 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts - AOL.com
Royal Bank Of Canada Forecasts Strong Price Appreciation for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock - MarketBeat
Mutual of America Capital Management LLC Sells 860 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by J. Safra Sarasin Holding AG - MarketBeat
Regeneron Soars 0.57% at 161st Trading Volume Rank as ALS Trial Gains Momentum - AInvest
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.17%
1.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):